Form 144 Filer Information

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 144

FORM 144

### NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

## **144: Filer Information**

Filer CIK	0001832794
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	● LIVE ◎ TEST
Submission Contact Information	
Name	
Phone	
E-Mail Address	

# **144: Issuer Information**

Name the Securities Exchange

Name of Issuer	MARAVAI LIFESCIENCES HOLDINGS, INC.
SEC File Number	001-39725
Address of Issuer	10770 Wateridge Circle Suite 200 San Diego CALIFORNIA 92121
Phone	858-546-0004
Name of Person for Whose Account the Securities are To Be Sold	Maravai Life Sciences Holdings 2, LLC

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer	Owner	
144: Securities Information		
Title of the Class of Securities To Be Sold	Class A common stock, par value \$0.01 per share	
Name and Address of the Broker	Goldman Sachs & Co. LLC 200 West Street New York NY 10282	
Number of Shares or Other Units To Be Sold	1531028	
Aggregate Market Value	16504481.84	
Number of Shares or Other Units Outstanding	132830872	
Approximate Date of Sale	05/28/2024	

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or

Nasdaq

144: Securities To Be Sold		
Title of the Class	Class A common stock, par value \$0.01 per share	
Date you Acquired	11/19/2020	
Nature of Acquisition Transaction	Pre-IPO reorganization	
Name of Person from Whom Acquired	Maravai LifeSciences Holdings, Inc.	
Is this a Gift?	Date Donor Acquired	
Amount of Securities Acquired	28965664	
Date of Payment	11/19/2020	
Nature of Payment	Securities of the issuer were received in connection with a series of reorganization transactions prior to the issuer's IPO.	

If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

## 144: Securities Sold During The Past 3 Months

Nothing to Report

1

## 144: Remarks and Signature

(1) Based on the closing price on May 28, 2024 of \$10.78. (2) As of May 2, 2024 (as reported on the Issuer's Form 10-Q for the quarter ended March 31, 2024, filed with the Securities and Exchange Commission on May 9, 2024).

Date of Notice

Remarks

05/28/2024

### ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Kevin Herde

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)